NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Acrivon Therapeutics, Inc. (ACRV) Stock Analysis

Acrivon Therapeutics, Inc. (ACRV) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ACRV

$1.83

+$0.03 (+1.67%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACRV with… →

ACRV Key Statistics

As of Oct 21, 2026
Trading
Open
$1.80
Previous Close
$1.80
Day's Range
1.80–1.88
52-Week Range
1.27–3.56
Volume
159.07K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.93
Valuation
Market Cap
$78.21M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.88
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$77.91M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
42.85M
1-Year Return
−10.54%
Dividend and dates
Avg Volume
319.18K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ACRV closed at $1.83, −10.54% over 1 year.

Acrivon Therapeutics, Inc. (ACRV) has a market capitalization of $78.21M.

In fiscal 2025, ACRV reported revenue of $0.00.

ACRV Stock Return by Calendar Year

Acrivon Therapeutics, Inc. (ACRV) return since Nov 2022: what $10,000 became

1 year
$10,000 $8,946
−10.54%
3 years
$10,000 $3,294
−67.06%
Since Nov 2022
$10,000 $1,097
−89.03%

If you had invested $10,000 in Acrivon Therapeutics, Inc. (ACRV) at the close on November 15, 2022, the earliest close on record here, it would have been worth $1,097 at the close on October 21, 2026: −89.03% in total, −43.00% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−24.27%
2025−59.97%
2024+22.36%
2023−57.29%
2022 (partial year)−30.77%

As of October 21, 2026.

ACRV Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$77.91M—
2024$0.00−$80.56M—
2023$0.00−$60.39M—
2022$0.00−$31.17M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$84.11M−$77.91M—
2024$0.00—−$89.20M−$80.56M—
2023$0.00—−$67.10M−$60.39M—
2022$0.00—−$32.66M−$31.17M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Acrivon Therapeutics, Inc. (ACRV) is capitalised at $78.21M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 74 employees.

ACRV last closed at $1.83 on October 21, 2026. That is +$0.03 (+1.67%) against the previous close. The 52-week range on file runs from $1.27 to $3.56. The latest close sits 43.7% above that 52-week low.

Financial Health

In fiscal 2025, Acrivon Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $77.91M. Trailing earnings per share are −1.88.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is −10.54%. Across 3 years the annualized return works out at −30.94%. The reported beta is 1.93. Daily returns over the trailing 3 years annualize to a volatility of 104.94%.

Growth & Income

No dividend is on file for ACRV.

The strongest complete calendar year on file is 2024 at +22.36%; the weakest is 2025 at −59.97%. Of the 3 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is −24.27% year to date.

Peer Comparison

Acrivon Therapeutics, Inc. (ACRV) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Acrivon Therapeutics, Inc. ACRV $78.21M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Acrivon Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Visit website →